Role of Type I Interferons in the Activation of Autoreactive B Cells
Overview
Cell Biology
Affiliations
Type I interferons (IFNs) are a family of cytokines involved in the defense against viral infections that play a key role in the activation of both the innate and adaptive immune system. IFNs both directly and indirectly enhance the capacity of B lymphocytes to respond to viral challenge and produce cytotoxic and neutralizing antibodies. However, prolonged type I IFN exposure is not always beneficial to the host. If not regulated properly IFN can drive autoantibody production as well as other parameters of systemic autoimmune disease. Type I IFNs impact B-cell function through a variety of mechanisms, including effects on receptor engagement, Toll-like receptor expression, cell migration, antigen presentation, cytokine responsiveness, cytokine production, survival, differentiation and class-switch recombination. Type I IFNs are also cytotoxic for a variety of cell types and thereby contribute to the accumulation of cell debris that serves as a potential source for autoantigens. Type I IFN engagement of a variety of accessory cells further promotes B-cell survival and activation, as exemplified by the capacity of type I IFNs to increase the level of B-cell survival factors, such as B lymphocyte stimulator, produced by dendritic cells. Therefore, it is not surprising that the loss of expression of the type I IFN receptor can have dramatic effects on the production of autoantibodies and on the clinical features of systemic autoimmune diseases such as systemic lupus erythematosus.
NETosis: A key player in autoimmunity, COVID-19, and long COVID.
Monsalve D, Acosta-Ampudia Y, Acosta N, Celis-Andrade M, Sahin A, Yilmaz A J Transl Autoimmun. 2025; 10:100280.
PMID: 40071133 PMC: 11894324. DOI: 10.1016/j.jtauto.2025.100280.
Pan X, Zhou F, Shi X, Liu Q, Yan D, Teng Q Vaccines (Basel). 2025; 13(2).
PMID: 40006646 PMC: 11861068. DOI: 10.3390/vaccines13020099.
Hong B, You S, Kim J, Kim M, Lee N, Lee K Front Immunol. 2025; 15:1439082.
PMID: 39877346 PMC: 11772891. DOI: 10.3389/fimmu.2024.1439082.
Bekaddour N, Smith N, Caspar B, Grinberg S, Giorgiutti S, Rodeschini V Front Immunol. 2024; 15:1490593.
PMID: 39737176 PMC: 11682962. DOI: 10.3389/fimmu.2024.1490593.
Zhang J, Mizuuchi Y, Ohuchida K, Hisano K, Shimada Y, Katayama N Cancer Sci. 2024; 116(2):500-512.
PMID: 39623744 PMC: 11786312. DOI: 10.1111/cas.16409.